AbbVie says EU approves Rinvoq for non-segmental vitiligo treatment

Reuters2026/07/29 07:00

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AbbVie won European Commission clearance for Rinvoq (upadacitinib) 15 mg once daily for non-segmental vitiligo in patients aged 12+.
Rinvoq becomes the EU’s first systemic treatment for the condition, expanding its dermatology franchise into a new indication.
Approval was backed by Phase 3 Viti-Up data showing significant facial and total-body repigmentation at week 48 versus placebo.
The drug remains under U.S. FDA review for non-segmental vitiligo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607290300PR_NEWS_USPR_____CG14449) on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AbbVie says EU approves Rinvoq for non-segmental vitiligo treatment

You may also like

Crypto prices